Skip to main content

SGLT-2 inhibitors

Medically reviewed by Carmen Pope, BPharm. Last updated on May 30, 2023.

Other names: sodium-glucose cotransporter-2 inhibitors

What are SGLT-2 inhibitors?

SGLT-2 inhibitor is an abbreviation for sodium-glucose cotransporter-2 inhibitors. SGLT-2 inhibitors are a class of medicine used to lower high blood glucose levels in people with type 2 diabetes. They may also be called gliflozins.

SGLT-2 inhibitors inhibit SGLT-2 proteins located in the renal tubules of the kidneys which are responsible for reabsorbing glucose back into the blood. As a result, more glucose is excreted in the urine. SGLT-2 inhibitors have been shown to be effective at lowering hemoglobin A1c levels, improving weight loss and lowering blood pressure. They carry a low risk of hypoglycemia (low blood sugar levels).

They are usually well tolerated. SGLT-2 inhibitors may be used in the treatment of type 2 diabetes and act independently of beta-cell function in the pancreas.

List of SGLT-2 inhibitors

View by  Brand | Generic
Drug Name Avg. Rating Reviews
empagliflozin systemic (Pro)
5.4
337 reviews
canagliflozin systemic (Pro)
5.9
265 reviews
dapagliflozin systemic (Pro)
4.7
180 reviews
ertugliflozin systemic (Pro)
5.3
13 reviews
bexagliflozin systemic (Pro)
10
1 review
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).

See also

Medical conditions treated or associated with SGLT-2 inhibitors:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.